Gene

ESR2

estrogen receptor 2

Explore in graph →CI-GENE-00001028HGNC:3468 ENSG00000140009 NCBI 2100 CIViC Approved

Curated evidence

Clinical evidence (7)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–7 of 7 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ESR2 alternative transcripts1
(prognostic)	Malignant Breast Neoplasm	Prognostic	B	Does Not Support Poor Outcome	4	submitted	EID9620 In a clinical study including 4 cohorts of 649, 398, 887 and 1375 patients respectively, beta-1 underexpression is not significantly correlated with decreased DFS (including in ERalpha positive patien… (full text at CIViC) PMID 25007965 · Wimberly et al., 2014 · Open in CIViC	civic
ESR2 beta-2 and beta-52
(prognostic)	Malignant Breast Neoplasm	Prognostic	B	Supports Better Outcome	4	submitted	EID9611 In a clinical trial including 105 patients, beta-2 expression is significantly associated with an increased RFS (p = 0.006) and OS (p= 0.0008) by a multivariate analysis. This significative correlatio… (full text at CIViC)

Cohorts

Alteration frequency by cohort (1)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved1 cohort row · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Hypodiploid Acute Lymphoid Leukemia (St Jude, Nat Genet 2013) all_stjude_2013	unmapped	Ssm	1	44	2.3%

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.

ESR2 underexpression beta-14
(prognostic)	Malignant Breast Neoplasm	Prognostic	B	Supports Poor Outcome	4	submitted	EID9613 In a clinical study including 903 patients, ERalpha negative patients with no expression of beta-1 is significantly correlated with decreased DFS (p < 0.0001). PMID 27810901 · Elebro et al., 2017 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Prognostic	B	Supports Poor Outcome	4	submitted	EID9618 In a clinical study including 177 patients ERalpha positive treated with tamoxifen and fluoxymesterone therapy, nuclear underexpression of beta-1 is significantly associated with decreased RFS (p = 0.… (full text at CIViC) PMID 25288324 · Reese et al., 2014 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Prognostic	B	Supports Poor Outcome	4	submitted	EID9619 In a clinical study including 571 patients TN, nuclear (mainly) underexpression of beta-1 is significantly associated with decreased OS (p = 0.007), decreased DFS (p = 0.009) and decreased distant MFS… (full text at CIViC) PMID 26070269 · Wang et al., 2015 · Open in CIViC	civic
Exemestane + TamoxifenSubstitutes	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	4	submitted	EID9612 In a clinical trial including 718 patients treated with exemestane (367) or tamoxifen (351), patients treated with tamoxifen and underexpressing beta-1 show a significant correlation with decreased DF… (full text at CIViC) PMID 26002610 · Speirs et al., 2015 · Open in CIViC	civic

ESR2 underexpression beta-14

(prognostic)

Malignant Breast Neoplasm

Prognostic

Supports Poor Outcome

submitted

EID9613

In a clinical study including 903 patients, ERalpha negative patients with no expression of beta-1 is significantly correlated with decreased DFS (p < 0.0001).

PMID 27810901 · Elebro et al., 2017 · Open in CIViC

civic

〃

Malignant Breast Neoplasm

Prognostic

Supports Poor Outcome

submitted

EID9618

In a clinical study including 177 patients ERalpha positive treated with tamoxifen and fluoxymesterone therapy, nuclear underexpression of beta-1 is significantly associated with decreased RFS (p = 0.… (full text at CIViC)

PMID 25288324 · Reese et al., 2014 · Open in CIViC

civic

〃

Malignant Breast Neoplasm

Prognostic

Supports Poor Outcome

submitted

EID9619

In a clinical study including 571 patients TN, nuclear (mainly) underexpression of beta-1 is significantly associated with decreased OS (p = 0.007), decreased DFS (p = 0.009) and decreased distant MFS… (full text at CIViC)

PMID 26070269 · Wang et al., 2015 · Open in CIViC

civic

Exemestane + TamoxifenSubstitutes

Malignant Breast Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID9612

In a clinical trial including 718 patients treated with exemestane (367) or tamoxifen (351), patients treated with tamoxifen and underexpressing beta-1 show a significant correlation with decreased DF… (full text at CIViC)

PMID 26002610 · Speirs et al., 2015 · Open in CIViC

civic